Mucin-Based Biotherapies for Pseudomonas Aeruginosa Lung Infection
Abstract
The purpose of this project is to demonstrate that MUC1-ED synthetic peptides protect against Pseudomonas aeruginosa lung infection using both in vitro and in vivo model systems. For months 1-12 of the project, studies were conducted demonstrating that MUC1-ED 20-, 40-, 60-,80-, and 100-mer peptides 1) bound to P. aeruginosa and its flagella; 2) inhibited P. aeruginosa and flagella binding to human lung cells, and bacterial motility; 3) were not cytotoxic to lung cells; 4) did not affect lung cell barrier formation; 5) exhibited no damage to mouse lung, liver or kidney; and 6) displayed appropriate lung bioavailability in vivo. For months 13-24 of the project, studies were performed demonstrating that 1) all peptides demonstrated appropriate pharmacokinetic parameters in vivo; and 2) the 80-mer and100-mer MUC1-ED peptides reduced lung infection and inflammation, and improved survival, when administered to mice simultaneously with or prior to sublethal or lethal infection with laboratory or clinical strains of P. aeruginosa, compared with scrambled control peptides.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2022
- Accession Number
- AD1172216
Entities
People
- Erik P. Lillehoj
Organizations
- University of Baltimore